<< Revenir à la page d'accueil
13th november 2012
Maison de la Chimie, Paris
Perspectives and conclusions
Fabien CALVO
Directeur de la Recherche de l'INCa, Directeur de l'Institut Cancer AVIESAN
⤢
Perspectives and conclusions
Key points from today's meeting
Oncogenesis DNA repair
Tumor cell signalling
Immune targeting of tumors
New developments for therapy
Overview of Cancer research in France
Accelerating translation of innovation to patients
Structures and Infrastructures: Molecular genetic centers
From genetic centers to personalized therapy
Predictive tests for therapy: tests should benefit to all patients
CLIP2: early phase clinical trial centres
CLIP2 network is strategic to PPPs
PPP on innovative molecules: 10 Month from call for project to study start
Access to clinical trial information for patients: the INCa registry
Access to care and innovation through CT: Network of clinical research nurses
Research management structures: CCCs (SIRIC) dedicated to translational / integrated research
Patient access to innovation : a mission for all institutions
Patient access to innovation : a joint program with the ANSM
Next steps
|«
«
▶||
»
»|
0:00:00